Skip to main content

Table 3 Estimated risk of death or chronic disability per 1 million population resulting from L. loa encephalopathy following mass treatment with Mectizan®, under conditions of: 1) no mass treatment; 2) mass treatment with no risk reduction strategy; and 3) mass treatment using REA, RAPLOA-40, RAPLOA-20, or combined REA/RAPLOA-40 to reduce risk of L. loa encephalopathy. Four scenarios are considered based on high and low prevalence of loiasis and onchocerciasis, respectively (defined in the Appendix - see additional file 1).

From: A Framework for Decision-Making for Mass Distribution of Mectizan® in Areas Endemic for Loa loa

Loiasis Prevalence High High Low Low
Onchocerciasis Prevalence High Low High Low
No Mectizan® treatment 0 0 0 0
Mectizan® treatment     
   No risk-reduction strategy 85.1 85.1 26.0 26.0
   REA 5.1 3.4 0.5 0.3
   RAPLOA-40 12.9 12.9 2.0 2.0
   RAPLOA-20 5.6 5.6 0.6 0.6
   REA/RAPLOA-40 12.4 11.0 2.0 1.9